# MUBD-DecoyMaker2.0

Introduction
-----------------------------------

MUBD-DecoyMaker2.0 is a Python GUI application to generate maximal unbiased benchmarking sets data sets for virtual drug screening. It can be run on Windows-based machine and has no dependency. 

Availability & Implementation
-----------------------------------

* Due to the large size, the Python GUI application has been uploaded to the cloud drives and is accessible from there：
  https://www.dropbox.com/s/dfa35t2jb0fnarx/MUBD-DecoyMaker2.0.exe?dl=0     (Outside China) or
  https://pan.baidu.com/s/110FJY6YHxcaUmI7fSyUSkw  (China)


Documentation
-----------------------------------

* The manual for the Python GUI application and the files for the case study are available at this website, i.e. 'manual.for.MUBD-Decoymaker2.0.pdf' and 'Case-ACM4-Agonists.zip'.


Installation
-----------------------------------

* For users, we recommend them to run the Python GUI application on Windows-based machines, as all the dependencies have been included.  
* Please note we used the machine with Intel Core(TM) i7-7700 CPU@3.60GHz and RAM of 16 GB for testing the tool on 17 data sets. The computation time is listed below for your informtation. 
5HT1F-AGO,48116 seconds
5HT1F-ANTA,2355 seconds
DRD5-AGO,2048s seconds
DRD5-ANTA,4457 seconds
HRH4-AGO,4542 seconds
HRH4-ANTA,8581 seconds
ACM4-AGO, 1882 seconds
ACM4-ANTA, 35942 seconds
OPRM-AGO, 55778 seconds
OPRM-ANTA, 20507 seconds
BRS-ANTA, 533 seconds
SSR2-ANTA, 92 seconds
AG22-ANTA, 2457 seconds
PE2R3-AGO, 6672 seconds
PE2R3-ANTA,43726 seconds
MTR1B-AGO, 31487 seconds
MTR1B-ANTA, 1901 seconds

References
-----------------------------------
Methodology and Datasets:
1. Xia, J.; Jin, H.; Liu, Z.; Zhang, L.; Wang, X.S., An unbiased method to build benchmarking sets for ligand-based virtual screening and its application to GPCRs. J. Chem. Inf. Model., 2014, 54 (5): 1433-1450. https://pubs.acs.org/doi/10.1021/ci500062f 
2. Xia, J.; Tilahun, E.L.; Kebede, E.H.; Reid, T.E.; Zhang, L.;Wang, X.S.,Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families. J. Chem. Inf. Model., 2015, 55 (2): 374-388.
https://pubs.acs.org/doi/10.1021/ci5005515
3. Xia, J.; Reid, T.E.; Wu, S.; Zhang, L.; Wang, X.S., Maximal Unbiased Benchmarking Data Sets for Human Chemokine Receptors and Comparative Analysis. J. Chem. Inf. Model., 2018, 58 (5): 1104-1120. https://pubs.acs.org/doi/10.1021/acs.jcim.8b00004

Important Applications in Targeted Drug Discovery:

1. Dou, X.; Huang, H.; Li, Y.; Jiang, L.; Wang, Y.; Jin, H.; Jiao, N.; Zhang, L.; Zhang, L.; Liu, Z., Multistage Screening Reveals 3-Substituted Indolin-2-One Derivatives as Novel and Isoform-Selective C-Jun N-Terminal Kinase 3 (Jnk3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases. J. Med. Chem., 2019, 62, 6645-6664.
2. Wang Y.; Dou X.; Jiang L.; Jin H.; Zhang L.; Zhang L.; Liu Z., Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia. Eur. J. Med. Chem., 2019,171, 221-234.
3. Dou, X.; Jiang, L.; Wang, Y.; Jin, H.; Liu, Z.; Zhang, L., Discovery of New Gsk-3beta Inhibitors through Structure-Based Virtual Screening. Bioorg. Med. Chem. Lett., 2018, 28, 160-166.
4. Kong, Y.; Bender, A.; Yan, A., Identification of Novel Aurora Kinase a (Aurka) Inhibitors Via Hierarchical Ligand-Based Virtual Screening. J. Chem. Inf. Model., 2018, 58, 36-47.
